Aptinyx (NASDAQ:APTX) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Aptinyx (NASDAQ:APTX) from a hold rating to a buy rating in a research report sent to investors on Tuesday, Zacks.com reports. Zacks Investment Research currently has $3.00 price objective on the stock.

According to Zacks, “Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company’s product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. “

A number of other equities analysts also recently weighed in on APTX. SVB Leerink lowered their target price on shares of Aptinyx from $12.00 to $10.00 and set an outperform rating for the company in a research note on Monday, December 20th. Cantor Fitzgerald reaffirmed an overweight rating on shares of Aptinyx in a research note on Wednesday, November 10th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Aptinyx has an average rating of Buy and a consensus target price of $7.00.

Shares of NASDAQ APTX opened at $2.92 on Tuesday. Aptinyx has a twelve month low of $2.06 and a twelve month high of $4.73. The firm has a fifty day simple moving average of $2.55 and a 200 day simple moving average of $2.51. The company has a market capitalization of $197.73 million, a PE ratio of -2.86 and a beta of 1.34. The company has a quick ratio of 21.07, a current ratio of 21.07 and a debt-to-equity ratio of 0.13.

Aptinyx (NASDAQ:APTX) last announced its earnings results on Tuesday, November 9th. The company reported ($0.31) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.31). During the same quarter in the prior year, the company posted ($0.24) EPS. As a group, equities analysts expect that Aptinyx will post -1.17 earnings per share for the current fiscal year.

In other news, CFO Ashish Khanna purchased 45,000 shares of the business’s stock in a transaction that occurred on Thursday, December 2nd. The shares were acquired at an average cost of $2.26 per share, for a total transaction of $101,700.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Norbert G. Riedel purchased 100,000 shares of the business’s stock in a transaction that occurred on Monday, December 6th. The shares were purchased at an average price of $2.23 per share, for a total transaction of $223,000.00. The disclosure for this purchase can be found here. Insiders have bought 150,400 shares of company stock valued at $337,660 over the last quarter. Corporate insiders own 7.94% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in APTX. Ergoteles LLC purchased a new position in Aptinyx during the second quarter worth about $419,000. XTX Topco Ltd purchased a new position in Aptinyx during the second quarter worth about $53,000. Vanguard Group Inc. boosted its holdings in Aptinyx by 6.2% during the second quarter. Vanguard Group Inc. now owns 1,808,522 shares of the company’s stock worth $5,118,000 after purchasing an additional 105,945 shares during the last quarter. Adams Street Partners LLC boosted its holdings in Aptinyx by 1.7% during the second quarter. Adams Street Partners LLC now owns 5,395,996 shares of the company’s stock worth $15,271,000 after purchasing an additional 90,124 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Aptinyx during the second quarter worth about $56,000. Institutional investors and hedge funds own 50.35% of the company’s stock.

Aptinyx Company Profile

Aptinyx Inc is a clinical stage biopharmaceutical company. It engages in the discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G.

Recommended Story: What is the Dividend Aristocrat Index?

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.